Making rabies prophylaxis more economical

Figures & data

Table 1. Basic demographic characteristics of the study subjects

Group	Group A	Group B
Number of subjects	79	102
Mean age (years)	20.81	22.80
SD	0.94	0.97
Range	19–24	17–32
Male/female ratio	27/52	45/57

Table 2. Adverse reactions among study subjects

	Group A	Group B
Total number	79 × 2	102 × 5
Local reactions (n)
Pain	8	29
Pruritus	2	8
Edema	3	2
Erythema	1	2
Systemic reactions (n)
Headache	2	5
Fever	2	5
Myalgia	0	3
Malaise	2	8
Sleepiness	5	8
Total (n, %)	25, 5.8%	70, 13.73%

Table 3. A comparison of the neutralizing antibody levels between the two groups

	D0	D7	D14	D45	D180	D360
Group A
Number of subjects	79	79	73	73	65	66
GMT, IU/ml
Value (95% CI)	0.29 (0.26–0.34)	1.12 (0.96–1.30)	21.90 (19.06–25.17)	8.28 (6.51–10.41)	4.13 (3.20–5.33)	3.72 (2.69–5.15)
Range, IU/ml	0.19–0.39	0.09–4.9	6.76–134.90	1.32–165.96	0.83–58.88	0.37–97.72
n ≥ 0.5 IU/ml (%)	0/79 (0)	70/79 (88.6%)	73/73 (100%)	73/73 (100%)	65/65 (100%)	62/66 (93.9%)
Group B
Number of subjects	102	102	102	100	58	20
GMT, IU/ml
Value (95% CI)	0.16 (0.10–0.28)	1.39 (1.17–1.67)	19.93 (16.99–23.37)	7.89 (6.73–9.26)	4.02 (3.12–5.19)	2.58 (1.546–4.31)
Range, IU/ml	0.07–0.44	0.11–46.77	1.91–169.82	1.55–165.96	0.79–37.15	0.52–15.49
n ≥ 0.5 IU/ml	0/102 (0)	89/102 (87.3%)	102/102 (100%)	100/100 (100%)	58/58 (100%)	20/20 (100%)

Figure 1. Neutralizing antibody concentration in group A and group B between D0 and D360.

Table 4. A comparison of several different rabies vaccination regimens

Regimen	Injection	Days	Number of clinical visits	Number of vaccinations	Dosage of each vaccine (ml)	Note
2- 1	IM	0, 7	2	3	1.5	In this study
ESSEN 5	IM	0, 3,7, 14, 28	5	5	2.5	WHO recommended
2–1-1	IM	0, 7, 21	3	4	2.0	In USA
four-dose	IM	0, 3,7, 14	4	4	2.0	WHO recommended
two-site	ID	0, 3,7, 28	4	8	0.8	WHO recommended
eight-site	ID	0, 7, 28, 91	4	14	1.4	WHO recommended
four-site	ID	0, 7, 28	3	7	0.7	By Mary J Warrell
one-week four-site	ID	0, 3, 7	3	12	1.2	By Shantavasinkul P